Related Experiment Video
Updated: Aug 6, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Alzheimer's disease: its diagnosis and pathogenesis
1Centre for Education and Research on Ageing, Concord Hospital, Department of Medicine, University of Sydney, Concord, New South Wales, Australia 2130.
International Review of Neurobiology
|August 31, 2001
Summary
This study explores the link between Alzheimer's disease (AD) and cerebral blood flow (CBF), suggesting impaired blood flow may be a common mechanism for various AD risk factors. Understanding this connection could lead to new AD treatments and prevention strategies.
Area of Science:
- Neuroscience
- Vascular Biology
- Gerontology
Background:
- Alzheimer's disease (AD) has numerous identified and putative risk factors.
- Previous research suggests associations between AD risk factors and cerebral blood flow (CBF).
- Vascular disease shares risk factors with AD, indicating potential common pathways.
Purpose of the Study:
- To present a hypothesis linking AD risk factors to cerebral blood flow (CBF).
- To explore the potential of targeting vascular mechanisms for AD treatment and prevention.
Main Methods:
- Review and synthesis of existing literature on AD risk factors and CBF.
- Analysis of associations between factors influencing CBF and AD risk.
- Integration of data on microvascular damage and cerebrovascular disease.
Main Results:
- Many AD risk factors are associated with decreased CBF (e.g., age, depression, head trauma).
- Factors increasing CBF (e.g., education, exercise, smoking, NSAIDs) show inverse associations with AD risk.
- The hypothesis aligns with data linking microvascular damage and impaired blood flow to cerebrovascular disease.
Conclusions:
- Reduced CBF may be a common mechanism underlying various AD risk factors.
- Understanding the AD-vascular disease interaction is crucial for pathogenesis insights.
- Intervention strategies successful in vascular disease may be applicable to AD prevention and treatment.
More Related Videos
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...